Cargando…

Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study

BACKGROUND: Primary SARS-CoV-2 vaccination has been shown to wane with time and provide lower protection from disease with new viral variants, prompting the WHO to recommend the administration of booster doses. We determined the safety and immunogenicity of homologous or heterologous boosters with C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rose, Winsley, Raju, Reshma, Babji, Sudhir, George, Anna, Madhavan, Ramya, Leander Xavier, Julian Vivek, David Chelladurai, Jenita Sharon, Nikitha, Origanti Sharon, Deborah, Arpitha Anbu, Vijayakumar, Shalini, Immanuel, Sushil, John, Jacob, Rupali, Priscilla, Abhilash, Kundavaram P.P., Mohan, Venkata Raghava, Tallapaka, Karthik Bharadwaj, Samuel, Prasanna, Kang, Gagandeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870748/ https://www.ncbi.nlm.nih.gov/pubmed/36712811 http://dx.doi.org/10.1016/j.lansea.2023.100141

Ejemplares similares

Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India
por: Chaudhary, Anita, et al.
Publicado: (2023)

Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152)
por: Munigela, Apoorva, et al.
Publicado: (2022)

Inactivated vaccine Covaxin/BBV152: A systematic review
por: Ahmed, Tousief Irshad, et al.
Publicado: (2022)

Pityriasis Rosea Following Covaxin (BBV152) Vaccination for COVID-19
por: Singh, Bhabani S. T. P., et al.
Publicado: (2022)

Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine
por: Infimate, DJ L, et al.
Publicado: (2022)

Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses
por: Kumar, Nathella Pavan, et al.
Publicado: (2021)

Humoral Immune Response to BBV152 (Covaxin) SARS-CoV-2 Vaccine in Patients on Hemodialysis
por: Vijayaraghavan, Radha, et al.
Publicado: (2023)

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center
por: Prasad, Narayan, et al.
Publicado: (2022)

Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India
por: Satpathi, Partha Sarathi, et al.
Publicado: (2022)

Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)®) and BBV-152 (Covaxin(TM)®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Two Cases of Double-Positive Antineutrophil Cytoplasmic Autoantibody and Antiglomerular Basement Membrane Disease After BBV152/Covaxin Vaccination
por: Prema, Jansi, et al.
Publicado: (2021)

Nephrotic Syndrome with Acute Kidney Injury after Covaxin (BBV152) COVID-19 Vaccination: A Case from India
por: Patel, Prem S., et al.
Publicado: (2023)

Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study
por: Bhatnagar, Tarun, et al.
Publicado: (2022)

“Covishield and Covaxin” – India's contribution to global COVID-19 pandemic
por: Raina, Sunil Kumar, et al.
Publicado: (2021)

Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
por: Das, Swarnali, et al.
Publicado: (2022)

Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
por: Sunagar, Raju, et al.
Publicado: (2022)

Comparison of in-hospital COVID-19 related outcomes between COVISHIELD and COVAXIN recipients
por: Suri, Tejas M., et al.
Publicado: (2022)

Bbv-152: Subacute thyroiditis: case report
Publicado: (2022)

BBV-152: Myocarditis and myositis: case report
Publicado: (2022)

BBV-152: Herpes zoster: case report
Publicado: (2022)

BBV-152: Reactivation of uveitis : case report
Publicado: (2022)

A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys
por: Singh, Prateek, et al.
Publicado: (2022)

Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELD(TM) and COVAXIN(®) induced immunity in COVID-19 exposed Indians
por: Rakshit, Srabanti, et al.
Publicado: (2023)

Adverse effects after first and second dose of covishield and covaxin: A longitudinal study
por: Mittal, Amit, et al.
Publicado: (2022)

BBV-152: Cutaneous small vessel vasculitis: case report
Publicado: (2021)

Bbv-152: Cutaneous small-vessel vasculitis: case report
Publicado: (2021)

2371. A study to describe the pattern of cutaneous adverse effects of COVID-19 vaccines (Covishield and Covaxin )
por: Mitra, Debdeep, et al.
Publicado: (2023)

Impact of prior vaccination with Covishield(TM) and Covaxin® on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study
por: Abhilash, Kundavaram Paul Prabhakar, et al.
Publicado: (2022)

Azd-1222/bbv-152: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Effectiveness of Covid-19 vaccines (Covishield(TM) and Covaxin (®)) in healthcare workers in Mumbai, India: A retrospective cohort analysis
por: Contractor, Aashish, et al.
Publicado: (2022)

Post COVID Vaccination (COVAXIN™ -BB152 V) Pauci-immune Crescentic Glomerulonephritis
por: Bansal, Shyam B., et al.
Publicado: (2022)

AZD-1222/BBV-152: Central nervous system demyelination: 29 case reports
Publicado: (2022)

A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects
por: Dotiwala, Farokh, et al.
Publicado: (2022)

Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey
por: Cherian, Somy, et al.
Publicado: (2021)

Clinical profile of ChAdOx1 nCoV-19- and BBV152-vaccinated individuals among hospitalized COVID-19 patients: a pair-matched study
por: Keri, Vishakh C., et al.
Publicado: (2022)

Client Satisfaction of Antiretroviral Therapy Service Delivery: A Cross-Sectional Study at an Antiretroviral Therapy Center
por: Nikitha, Origanti Sharon, et al.
Publicado: (2021)

Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)?
por: Houshmand, Behzad, et al.
Publicado: (2022)

Prevalence, severity, and risk factor of breakthrough infection after vaccination with either the Covaxin or the Covishield among healthcare workers: A nationwide cross-sectional study
por: Krishna, Bhavya, et al.
Publicado: (2022)

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
por: Yadav, Pragya D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t49b1ndibsrg0girn44u38gs9p